301075 Tibet Duo Rui Pharmaceutical
- 19.23
- +0.84+4.57%
Tibet Duo Rui Pharmaceutical News
Dorui Pharmaceuticals (301075.SZ) announced first-quarter results, with a net loss of 2,5373 million yuan, an increase of 4.97% over the previous year
Dorui Pharmaceuticals (301075.SZ) released its report for the first quarter of 2024, with revenue of 784.574 million...
Dorui Pharmaceuticals (301075.SZ): 2023 net profit of 18.857,700 yuan, plans to distribute 10 to 1.25 yuan
On April 17, Ge Longhui Pharmaceutical (301075.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 334 million yuan, a year-on-year decrease of 16.64%; net profit attributable to shareholders of listed companies was 18.8507 million yuan, a year-on-year decrease of 8.05%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 5.258 million yuan, a year-on-year decrease of 34.96%; basic earnings per share of 0.24 yuan; it plans to distribute a cash dividend of 1.25 yuan (tax included) for every 10 shares to all shareholders.
Dorui Pharmaceutical (301075.SZ): A total cost of 19.178,900 yuan to buy back 1.19% of the shares
Glonghui, March 29丨Dorui Pharmaceutical (301075.SZ) announced that as of March 28, 2024, the company had repurchased 955,300 shares of the company's shares through a special stock repurchase securities account, accounting for 1.19% of the company's current total share capital. The highest transaction price was 21.10 yuan/share, the lowest transaction price was 18.21 yuan/share, and the total transaction amount was 19,178,878.41 yuan.
Dorui Pharmaceutical (301075.SZ): Proposed construction of pharmaceutical raw materials and intermediates projects
On March 20, Gelonghui Pharmaceutical (301075.SZ) announced that in order to enrich the production platform for pharmaceutical intermediates and APIs and further improve the company's industrial chain layout, Tibet Dorui Pharmaceutical Co., Ltd. plans to sign a “Contract for Investment in the Construction of Pharmaceutical Ingredients and Intermediates Projects” with the Yicheng Municipal People's Government. The project is located in the Xiangyang (Yicheng) Fine Chemical Industrial Park and covers an area of 128 acres. The details are as specified in the state-owned land use rights concession contract. The project aims to make full use of the location advantages of Yicheng Fine Chemical Park, rely on the existing foundation of the subsidiary Hubei Xinchengda Chemical Co., Ltd. to enrich pharmaceutical intermediates and
Dorui Pharmaceuticals (301075.SZ): Repurchase 100,000 shares for the first time on March 4
Gelonghui, March 5, 丨 Dorui Pharmaceutical (301075.SZ) announced that on March 4, 2024, the company repurchased 100,000 shares of the company's shares through a dedicated repurchase account, accounting for 0.13% of the company's current total share capital. The highest transaction price was 19.00 yuan/share, the lowest transaction price was 18.60 yuan/share, and the total transaction amount was 1,886,995.41 yuan (excluding transaction fees).
Dorui Pharmaceutical (301075.SZ): Plans to spend 20 million yuan to 30 million yuan to buy back the company's shares
On February 5, Gelonghui Pharmaceutical (301075.SZ) announced that the company plans to repurchase shares to protect the company's value and shareholders' rights. The total capital to be repurchased shall not be less than RMB 20 million and not more than RMB 30 million; the price range of the shares to be repurchased shall not exceed RMB 36 per share. Based on the maximum repurchase capital of RMB 30 million and the upper limit of the repurchase price of RMB 36 per share, the estimated number of shares to be repurchased is 833,333 shares, accounting for 1.04% of the company's total issued share capital; according to the lower limit of the total repurchase amount of RMB 20 million, return
Dorui Pharmaceutical (301075.SZ) plans to hold Hongxi Medical to enter the field of chronic kidney disease management
Dorui Pharmaceutical (301075.SZ) announced that the company recently signed an “Investment Cooperation Agreement”, and the company received it for 200,000 yuan...
Dorui Pharmaceutical (301075.SZ): Plans to transfer 51% of Hongxi Medical's shares for $0.0,000 (unpaid)
Gelonghui, January 17丨Dorui Pharmaceutical (301075.SZ) announced that in order to further enrich the company's business layout and create new profit growth points, Tibet Dorui Pharmaceutical Co., Ltd. recently signed an “Investment Cooperation Agreement”. The company took over the shares of Hongxi Medical Technology (Tianjin) Co., Ltd. (“Hongxi Medical” for short, the “Target Company”) held by Li Zhanbing, Tian Bin, Zhang Hengrui, and Xiong Rongliang with a registered capital of 5.1 million yuan (unpaid). The company will invest 5.1 million yuan in Hongxi Medical to fulfill the obligation to pay the capital. After the equity transfer was completed, the company held Hongxi Healthcare
Jiaxing Qiuyu, a shareholder of Dorui Pharmaceuticals (301075.SZ), completed a cumulative reduction of 2% of shares
Dorui Pharmaceutical (301075.SZ) announced that the company's shareholder Jiaxing Qiuyu's holdings reduction plan has expired, and it has passed centralized bidding...
The controlling shareholder of Dorui Pharmaceuticals (301075.SZ) lifted the pledge of 4.1 million shares
Dorui Pharmaceutical (301075.SZ) announced that the company's holding stock is Xizang Jiakang Times Technology Development Co., Ltd. (“West...
Jiaxing Qiuyu, a shareholder of Dorui Pharmaceutical (301075.SZ), reduced its shareholding ratio by a total of 1%
Duorui Pharmaceutical (301075.SZ) announced that the company's shareholder Jiaxing Qiuyu invests in partnership (limited partnership) (“Jia...
Dorui Pharmaceutical (301075.SZ): Wholly-owned subsidiary tranexamic acid injection obtained drug registration certificate
On November 20, Gelonghui Pharmaceutical (301075.SZ) announced that Hubei Duorui Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for tranexamic acid injections approved and issued by the State Drug Administration. Indications for tranexamic acid injection: This product is mainly used for various types of bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. According to data from Mi Intranet on the competitive pattern of chemical drug terminals in urban public hospitals in China, the sales volume of tranexamic acid injections in 2020-2022 was 378.37 million yuan and 644.4 million yuan in that order
Duorui Pharmaceutical (301075.SZ): Cancellation of Tibet Shengyun Industrial Co., Ltd., a wholly-owned subsidiary
Gelonghui, September 27丨Duorui Pharmaceutical (301075.SZ) announced that in order to improve the company's asset management efficiency, optimize the investment structure, and reduce management costs, the company recently cancelled its wholly-owned subsidiary, Tibet Shengyun Industrial Co., Ltd.
Dorui Pharmaceutical (301075.SZ): Jiaxing Qiuyu has reduced its share holdings by a cumulative total of 1.00%
GLONGHUI, August 14丨Dorui Pharmaceutical (301075.SZ) announced that from August 9 to 11, 2023, Jiaxing Qiuyu Investment Partnership (Limited Partnership) (“Jiaxing Qiuyu”) reduced its holdings of the company's shares by 820 million shares through centralized bidding, a reduction ratio of 1.00%. Currently, not all of the holdings reduction plans have been implemented.
Dorui Pharmaceutical (301075.SZ): No raw materials for diet pills
GLONGHUI August 11丨Some investors asked Dorui Pharmaceuticals (301075.SZ), “I heard that the company has ingredients for diet pills, is that true?” Dorui Pharmaceutical replied that the company had no relevant APIs.
Dorui Pharmaceutical (301075.SZ) plans to acquire 55% of Xincheng's shares to improve the layout of the pharmaceutical industry chain
According to the Zhitong Finance App, Dorui Pharmaceutical (301075.SZ) announced that the company signed an “Investment Cooperation Agreement” with Shengxiang Chemical, Wuhan Jinshengxing Automatic Control Engineering Co., Ltd. (“Jin Shengxing”), and Xin Chengda, to transfer 30.5% and 7.625% of the shares of Xinchengda held by Shengxiang Chemical and Jin Shengxing respectively with its own capital or self-financing of RMB 30.00 million (including prepaid funds of RMB 20 million) Xin Chengda increased its capital. After the transaction is completed, the registered capital of the target company is 103 million yuan, and the company will
Dorui Pharmaceutical (301075.SZ): Classic recipes of traditional Chinese medicine are in the trial/pilot study stage
Gronway July 28丨Some investors asked Dorui Pharmaceuticals (301075.SZ), “What is your company doing in the field of traditional Chinese medicine? What products are already available?” Dorui Pharmaceutical replied that currently, the new class 1 traditional Chinese medicine being developed by the company is preparing for phase II clinical trials. Classic recipes of traditional Chinese medicines are in the trial/pilot study stage. For the relevant situation, please pay attention to the regular reports and related announcements.
Dori Pharmaceutical: in order to further optimize the equity investment structure, it is proposed to acquire the remaining 20% stake in the holding subsidiary Jiaruokang.
Dori Pharmaceutical (301075) announced that in order to further optimize the company's equity investment structure and improve the operational efficiency of the R & D platform, the company plans to use its own funds to acquire a 20 per cent stake in Wuhan Jia Nuokang Pharmaceutical Technology Co., Ltd., a holding subsidiary of Wuhan Pharmaceutical Technology Co., Ltd. The two sides of the transaction recently signed the "Equity transfer Agreement". Upon completion of the transaction, Jianokang will become a wholly owned subsidiary of the company.
Tori Pharmaceutical (301075.SZ): plans to use 26.3 million yuan of super-raised funds for permanent replenishment
301075.SZ announced that the company held the ninth meeting of the first session of the Board of Directors and the eighth meeting of the first session of the Supervisory Committee on December 24, 2021, and examined and passed the "motion on the use of part of the over-raised funds to permanently replenish current funds", agreeing that the company should use 26.3 million yuan of over-raised funds for permanent replenishment of liquidity. The bill still needs to be submitted to the company's first interim general meeting of shareholders in 2022 for consideration and approval.
301075.SZ: it is proposed to use no more than 100 million yuan of idle self-owned funds for cash management.
301075.SZ announced that the company held the eighth meeting of the first board of directors and the seventh meeting of the first board of supervisors on December 10, 2021, and passed the "motion on the use of the company's idle self-owned funds for cash management", agreeing to ensure the liquidity and safety of the company and its subsidiaries. The company and its subsidiaries intend to use idle self-owned funds of no more than RMB 100 million yuan (including capital) for cash management, within which the funds can be used on a rolling basis, and the management period shall be valid within 12 months from the date of examination and approval by the board of directors. meanwhile
Analysis
Price Target
No Data
